title: The clinical application of chronobiology to oncology.
abstract: The introduction to medical practice of chemical agents for fighting human cancer some 30 years ago brought hope to a field of medicine previously shrouded in despair and impeded by superstition. Gradually more and better agents have become available to the physician and to the patient suffering from cancer. The physician-scientist has, in turn, learned a great deal about normal and abnormal cellular biology by using these drugs as probes. The observations that certain tissues and certain tumors share patterns of drug toxicity have led to a broadening of biologic understanding and to the use of combinations of drugs with shared antitumor activity and unshared toxicities. This empiric art of cancer chemotherapy has resulted in great progress in the treatment of a large number of advanced cancers. As important, however, is that this experience has resulted in knowledge which is leading to the development of rationally designed therapeutic regimens; to drug analogues seeking greater therapeutic-toxic ratios; to the development of methods for chemically interfering with toxic drug effects while allowing or enhancing antitumor effect; and to work defining effects of drug timing. Drug timing research considers drug dosage in respect to the timing of a drug relative to the timing of other drugs (drug-time-drug interactions) or to other doses of that same drug (drug-drug interval); the order of drugs (drug-drug sequence); and the timing of drugs relative to an internal organismic time structure (time-drug interactions). Data in this brief review clearly show that drug timing needs to be considered when designing rational chemotherapy for a living organism suffering from a cancer. The beautiful spatiotemporal complexity of life is not to be ignored or avoided, but should be considered as a golden opportunity to use what few imprecise chemical weapons we have a little more effectively.
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000633:toxicity / Q000652:urine; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001683:Biological Clocks; D001853:Bone Marrow / Q000187:drug effects; D001943:Breast Neoplasms / Q000503:physiopathology; D002455:Cell Division; D002945:Cisplatin / Q000008:administration & dosage / Q000633:toxicity; D004064:Digestive System / Q000187:drug effects; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006728:Hormones / Q000502:physiology; D006801:Humans; D007109:Immunity; D007668:Kidney / Q000187:drug effects; D007700:Kinetics; D007939:Leukemia L1210 / Q000188:drug therapy; D008214:Lymphocytes / Q000032:analysis; D008495:Medical Oncology / Q000379:methods*; D051379:Mice; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000401:mortality; D011315:Preventive Medicine / Q000379:methods; D012313:RNA / Q000032:analysis; D051381:Rats; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D006728:Hormones; D012313:RNA; D004317:Doxorubicin; D002945:Cisplatin